May 4, 2015 -- Shanghai Generon Corporation has been granted FDA approval to begin a US Phase IIa clinical trial of its novel recombinant human interleukin. The molecule will be tested as a treatment for graft-versus-host disease in the lower intestines of patients undergoing hematopoietic stem cell transplants, a side-effect with incidence as high as 50%. Generon says the drug offers a treatment alternative that, instead of increasing immune suppression, aims to regenerate the intestines.
Help employers find you! Check out all the jobs and post your resume.
